TT, these are all great statements but why don’t they reveal the actual split of trial v commercial sales? Instead all we get every single quarter is circa $100K revenue and $3 million of cash burning costs. Hence, the market remains unimpressed with every announcement.
Ann: 200th patient treated with the OncoSil device, page-3
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.001(7.69%) |
Mkt cap ! $23.78M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $34.37K | 5.002M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 4929003 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 23400459 | 26 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |